Drug-Associated Mitochondrial Toxicity

Drug-Induced Mitochondrial Dysfunction

Volumn , Issue , 2008, Pages 71-126

  Mehta, Rhea ^a   Chan, Katie ^a   Lee, Owen ^a   Tafazoli, Shahrzad ^a   O'Brien, Peter J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Drug associated mitochondrial toxicity; Drug induced hepatic cholestatic injury; Membrane interaction QSAR analysis

Indexed keywords

EID: 84889382501     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470372531.ch3     Document Type: Chapter

References (187)

1. Sato K, Ueda Y, Ueno K, Okamoto K, Iizuka H, Katsuda S. Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. Virchows Arch. 2005;447:996-999.
2. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol. 1996;52:273-280.
3. Pankow JS, Duncan BB, Schmidt MI, et al. Fasting plasma free fatty acids and risk of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes Care. 2004;27:77-82.
4. Di Paola M, Lorusso M. Interaction of free fatty acids with mitochondria: coupling, uncoupling and permeability transition. Biochim Biophys Acta. 2006;1757:1330-1337.
5. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology. 1998;27:128-133.
6. Caro AA, Cederbaum AI. Role of intracellular calcium and phospholipase A2 in arachidonic acid-induced toxicity in liver cells overexpressing CYP2E1. Arch Biochem Biophys. 2007;457:252-263.
7. Di Paola M, Zaccagnino P, Oliveros-Celis C, Lorusso M. Arachidonic acid induces specific membrane permeability increase in heart mitochondria. FEBS Lett. 2006;580:775-781.
8. Wanders RJ, Tager JM. Lipid metabolism in peroxisomes in relation to human disease. Mol Aspects Med. 1998;19:69-154.
9. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology. 2006;43:S31-S44.
10. Feldstein AE,Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004;40:185-194.
11. Feldstein AE, Werneburg NW, Li Z, Bronk SF, Gores GJ. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1339-G1346.
12. Unger RH. Lipotoxic diseases. Annu Rev Med. 2002;53:319-336.
13. Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis lead to invivo lipid peroxidation in mice. J Hepatol. 1996;24:200-208.
14. Eaton S, Zaitoun AM, Record CO, Bartlett K. Beta-oxidation in human alcoholic and non-alcoholic hepatic steatosis. Clin Sci (Lond). 1996;90:307-313.
15. Freneaux E, Labbe G, Letteron P, et al. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology. 1988;8:1056-1062.
16. Deboyser D, Goethals F, Krack G, Roberfroid M. Investigation into the mechanism of tetracycline-induced steatosis: study in isolated hepatocytes. Toxicol Appl Pharmacol. 1989;97:473-479.
17. Labbe G, Fromenty B, Freneaux E, et al. Effects of various tetracycline derivatives on in vitro and in vivo beta-oxidation of fatty acids, egress of triglycerides from the liver, accumulation of hepatic triglycerides, and mortality in mice. Biochem Pharmacol. 1991;41:638-641.
18. Damjanov I, Solter D. Ultrastructure of acute tetracycline induced liver change. Experientia. 1971;27:1204-1205.
19. Du Buy HG, Showacre JL. Selective localization of tetracycline in mitochondria of living cells. Science. 1961;133:196-197.
20. Combes B, Whalley PJ, Adams RH. Tetracycline and the liver. Prog Liver Dis. 1972;4:589-596.
21. Geneve J, Hayat-Bonan B, Labbe G, et al. Inhibition of mitochondrial beta-oxidation of fatty acids by pirprofen: role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J Pharmacol Exp Ther. 1987;242:1133-1137.
22. Fromenty B, Freneaux E, Labbe G, et al. Tianeptine, a new tricyclic antidepressant metabolized by beta-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice. Biochem Pharmacol. 1989;38:3743-3751.
23. Le Dinh T, Freneaux E, Labbe G, et al. Amineptine, a tricyclic antidepressant, inhibits the mitochondrial oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther. 1988;247:745-750.
24. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol . 2005;42:928-940.
25. Lelliott CJ, Lopez M, Curtis RK, et al. Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J. 2005;19:1108-1119.
26. Petit F, Fromenty B, Owen A, Estaquier J. Mitochondria are sensors for HIV drugs. Trends Pharmacol Sci. 2005;26:258-264.
27. Anderson N, Borlak J. Drug-induced phospholipidosis. FEBS Lett. 2006;580:5533-5540.
28. Yamamoto A, Adachi S, Matsuzawa Y, Kitani T, Hiraoka A, Seki K. Studies on drug-induced lipidosis: VII. Effects of bis-beta-diethyl-aminoethylether of hexestrol, chloroquine, homochlorocyclizine, prenylamine, and diazacholesterol on the lipid composition of rat liver and kidney. Lipids. 1976;11:616-622.
29. Kubo M, Hostetler KY. Metabolic basis of diethylaminoethoxyhexestrol-induced phospholipid fatty liver. Am J Physiol. 1987;252:E375-E379.
30. Berson A, De B, V, Letteron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology. 1998;114:764-774.
31. Varbiro G, Toth A, Tapodi A, Veres B, Sumegi B, Gallyas F, Jr. Concentration dependent mitochondrial effect of amiodarone. Biochem Pharmacol. 2003;65:1115-1128.
32. Fromenty B, Fisch C, Berson A, Letteron P, Larrey D, Pessayre D. Dual effect of amiodarone on mitochondrial respiration: initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J Pharmacol Exp Ther. 1990;255:1377-1384.
33. Kaufmann P, Torok M, Hanni A, Roberts P, Gasser R, Krahenbuhl S. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology. 2005;41:925-935.
34. Waldhauser KM, Torok M, Ha HR, et al. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J Pharmacol Exp Ther. 2006;319:1413-1423.
35. Bandyopadhyay S, Klaunig JE, Somani P. Cytotoxic interactions of cardioactive cationic amphiphilic compounds in primary rat hepatocytes in culture. Hepatology. 1990;12:48-58.
36. Christopoulos A, Grant MK, Ayoubzadeh N, et al. Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther. 2001;298:1260-1268.
37. Card JW, Racz WJ, Brien JF, Margolin SB, Massey TE. Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicol Sci. 2003;75:169-180.
38. Reasor MJ, McCloud CM, Beard TL, et al. Hostetler KY. Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats. Toxicology. 1996;106:139-147.
39. Dieterle F, Ross A, Schlotterbeck G, Senn H. Metabolite projection analysis for fast identification of metabolites in metabonomics: application in an amiodarone study. Anal Chem. 2006;78:3551-3561.
40. Sawada H, Takami K, Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel invitro screening system. Toxicol Sci. 2005;83:282-292.
41. Agoston M, Orsi F, Feher E, et al. Silymarin and vitamin E reduce amiodarone-induced lysosomal phospholipidosis in rats. Toxicology. 2003;190:231-241.
42. Pessayre D, Bichara M, Degott C, Potet F, Benhamou JP, Feldmann G. Perhexiline maleate-induced cirrhosis. Gastroenterology. 1979;76:170-177.
43. Deschamps D, DeBeco V, Fisch C, Fromenty B, Guillouzo A, Pessayre D. Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology. 1994;19:948-961.
44. Hostetler KY, Reasor M, Yazaki PJ. Chloroquine-induced phospholipid fatty liver: measurement of drug and lipid concentrations in rat liver lysosomes. J Biol Chem. 1985;260:215-219.
45. Almotrefi AA. Effects of class I antiarrhythmic drugs on mitochondrial ATPase activity in guinea pig heart preparations. Gen Pharmacol. 1993;24:233-237.
46. Mironova GD, Grigoriev SM, Skarga Y, Negoda AE, Kolomytkin OV. ATP-dependent potassium channel from rat liver mitochondria: inhibitory analysis, channel clusterization. Membr Cell Biol. 1997;10:583-591.
47. Wold JS, Joost RR, Griffing WJ. Phospholipid accumulation in rats produced by fluoxetine and chlorphentermine. Toxicol Appl Pharmacol. 1976;37:118-119.
48. Berson A, Fau D, Fornacciari R, et al. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol. 2001;34:261-269.
49. Berson A, Renault S, Letteron P, et al. Uncoupling of rat and human mitochondria: a possible explanation for tacrine-induced liver dysfunction. Gastroenterology. 1996;110:1878-1890.
50. Mansouri A, Haouzi D, Descatoire V, et al. Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver. Hepatology. 2003;38:715-725.
51. Luef GJ, Waldmann M, Sturm W, et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol. 2004;55:729-732.
52. Sugimoto T,WooM, Nishida N, Takeuchi T, Sakane Y, Kobayashi Y. Hepatotoxicity in rat following administration of valproic acid. Epilepsia. 1987;28:142-146.
53. Spahr L, Negro F, Rubbia-Brandt L, et al. Acute valproate-associated microvesicular steatosis: Could the [13C]methionine breath test be useful to assess liver mitochondrial function? Dig Dis Sci. 2001;46:2758-2761.
54. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther. 1995;67:101-154.
55. Baldwin GS, Abbott FS, Nau H. Binding of a valproate metabolite to the trifunctional protein of fatty acid oxidation. FEBS Lett. 1996;384:58-60.
56. Natarajan SK, Eapen CE, Pullimood AB, Balasubramanian KA. Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes. J Gastroenterol Hepatol. 2006;21:1240-1249.
57. Tong V, Teng XW, Chang TK, Abbott FS. Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol Sci. 2005;86:427-435.
58. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1-28.
59. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell . 2006;127:1109-1122.
60. Baur JA, Pearson KJ, Price NL, et al. Lakatta EG, Le Couteur D, Shaw RJ, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337-342.
61. Patel T, Gores GJ. Inhibition of bile-salt-induced hepatocyte apoptosis by the antioxidant lazaroid U83836E. Toxicol Appl Pharmacol. 1997;142:116-122.
62. Rolo AP, Palmeira CM, Wallace KB. Interactions of combined bile acids on hepatocyte viability: cytoprotection or synergism. Toxicol Lett. 2002;126:197-203.
63. Rolo AP, Oliveira PJ, Moreno AJ, Palmeira CM. Bile acids affect liver mitochondrial bioenergetics: possible relevance for cholestasis therapy. Toxicol Sci. 2000;57:177-185.
64. Palmeira CM, Rolo AP. Mitochondrially-mediated toxicity of bile acids. Toxicology. 2004;203:1-15.
65. Gumpricht E, Dahl R, Devereaux MW, Sokol RJ. Licorice compounds glycyrrhizin and 18beta-glycyrrhetinic acid are potent modulators of bile acid-induced cytotoxicity in rat hepatocytes. J Biol Chem. 2005;280:10556-10563.
66. Sokol RJ, Dahl R, Devereaux MW, Yerushalmi B, Kobak GE, Gumpricht E. Human hepatic mitochondria generate reactive oxygen species and undergo the permeability transition in response to hydrophobic bile acids. J Pediatr Gastroenterol Nutr. 2005;41:235-243.
67. Yerushalmi B, Dahl R, Devereaux MW, Gumpricht E, Sokol RJ. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology. 2001;33:616-626.
68. Sodeman T, Bronk SF, Roberts PJ, Miyoshi H, Gores GJ. Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas. Am J Physiol Gastrointest Liver Physiol. 2000;278:G992-G999.
69. Guicciardi ME, Gores GJ. Cholestatic hepatocellular injury: What do we know and how should we proceed? J Hepatol. 2005;42:297-300.
70. Higuchi H, Gores GJ. Bile acid regulation of hepatic physiology: IV. Bile acids and death receptors. Am J Physiol Gastrointest Liver Physiol. 2003;284:G734-G738.
71. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002;123:1649-1658.
72. Siraki AG, Pourahmad J, Chan TS, Khan S, O'Brien PJ. Endogenous and endobiotic induced reactive oxygen species formation by isolated hepatocytes. Free Radic Biol Med. 2002;32:2-10.
73. Shen HM, Liu ZG. JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med. 2006;40:928-939.
74. Pourahmad J, Khan S, O'Brien PJ. Lysosomal oxidative stress cytotoxicity induced by nitrofurantoin redox cycling in hepatocytes. Adv Exp Med Biol. 2001;500:261-265.
75. Terman A, Gustafsson B, Brunk UT. The lysosomal-mitochondrial axis theory of postmitotic aging and cell death. Chem Biol Interact. 2006;163:29-37.
76. Chan K, Truong D, Shangari N, O'Brien PJ. Drug-induced mitochondrial toxicity. Expert Opin Drug Metab Toxicol. 2005;1:655-669.
77. Degli EM. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim Biophys Acta. 1998;1364:222-235.
78. Miyoshi H. Inhibitors of mitochondrial respiratory enzymes. J Pestic Sci. 2005;30:120-121.
79. Caboni P, Sherer TB, Zhang N, et al. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. Chem Res Toxicol. 2004;17:1540-1548.
80. Li N, Ragheb K, Lawler G, et al. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem. 2003;278:8516-8525.
81. Annepu J, Ravindranath V. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced complex I inhibition is reversed by disulfide reductant, dithiothreitol in mouse brain. Neurosci Lett. 2000;289:209-212.
82. Guth PS, Spirtes MA. The phenothiazine tranquilizers: biochemical and biophysical actions. Int Rev Neurobiol. 1964;12:231-278.
83. Balijepalli S, Boyd MR, Ravindranath V. Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation. Neuropharmacology. 1999;38:567-577.
84. Maurer I, Moller HJ. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol Cell Biochem. 1997;174:255-259.
85. Igarashi K, Kasuya F, Fukui M, Usuki E, Castagnoli N, Jr.. Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP. Life Sci. 1995;57:2439-2446.
86. Rollema H, Skolnik M, D'Engelbronner J, Igarashi K, Usuki E, Castagnoli N, Jr.. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther. 1994;268:380-387.
87. Veitch K, Hue L. Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism. Mol Pharmacol. 1994;45:158-163.
88. Sztark F, Nouette-Gaulain K, Malgat M, Dabadie P, Mazat JP. Absence of stereospecific effects of bupivacaine isomers on heart mitochondrial bioenergetics. Anesthesiology. 2000;93:456-462.
89. Johnson ME, Uhl CB, Spittler KH, Wang H, Gores GJ. Mitochondrial injury and caspase activation by the local anesthetic lidocaine. Anesthesiology. 2004;101:1184-1194.
90. Hanley PJ, Ray J, Brandt U, Daut J. Halothane, isoflurane and sevoflurane inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac mitochondria. J Physiol. 2002;544:687-693.
91. Tanaka S, Ohta S, Shimonaka H, et al. The effects of dantrolene on the respiratory function in isolated rat liver mitochondria. Masui (Japanese Journal of Anesthesiology). 1986;35:755-761.
92. Haettinger JR, Mackerer CR, Colton DG, Mehlman MA. Effects of 5,5'-diphenyl-2-thiohydantoin on respiration and oxidative phosphorylation of rat liver mitochondria. Chem Biol Interact. 1975;10:255-264.
93. Becuwe P, Dauca M. Comparison of cytotoxicity induced by hypolipidemic drugs via reactive oxygen species in human and rodent liver cells. Int J Mol Med. 2005;16:483-492.
94. Qu B, Li QT, Wong KP, Tan TM, Halliwell B. Mechanism of clofibrate hepatotoxicity: mitochondrial damage and oxidative stress in hepatocytes. Free Radic Biol Med. 2001;31:659-669.
95. Keller BJ, Yamanaka H, Thurman RG. Inhibition of mitochondrial respiration and oxygen-dependent hepatotoxicity by six structurally dissimilar peroxisomal proliferating agents. Toxicology. 1992;71:49-61.
96. Brunmair B, Lest A, Staniek K, et al. Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp Ther. 2004;311:109-114.
97. Zhou S, Wallace KB. The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicol Sci. 1999;48:82-89.
98. Chan NN, Brain HP, Feher MD. Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diabet Med. 1999;16:273-281.
99. El Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275:223-228.
100. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348 (pt 3): 607-614.
101. Brunmair B, Staniek K, Gras F, et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes. 2004;53:1052-1059.
102. Tirmenstein MA, Hu CX, Gales TL, et al. Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol Sci. 2002;69:131-138.
103. Masubuchi Y, Kano S, Horie T. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology. 2006;222:233-239.
104. Tafazoli S, O'Brien PJ. Peroxidases: a role in the metabolism and side effects of drugs. Drug Discov Today. 2005;10:617-625.
105. Narayanan PK, Hart T, Elcock F, et al. Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment. Cytometry A. 2003;52:28-35.
106. Smith MT. Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol. 2003;16:679-687.
107. Fau D, Eugene D, Berson A, et al. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther. 1994;269:954-962.
108. Waterfield CJ, Delaney J, Kerai DJ, Timbrell JA. Correlations between invivo and invitro effects of toxic compounds: studies with hydrazine. Toxicol invitro. 1997;11:217-227.
109. Chan TS, Teng S, Wilson JX, Galati G, Khan S, O'Brien PJ. Coenzyme Q cytoprotective mechanisms for mitochondrial complex I cytopathies involves NAD(P)H:quinone oxidoreductase 1(NQO1). Free Radic Res. 2002;36:421-427.
110. Sun J, Trumpower BL. Superoxide anion generation by the cytochrome bc1 complex. Arch Biochem Biophys. 2003;419:198-206.
111. Khan S, O'Brien PJ. Modulating hypoxia-induced hepatocyte injury by affecting intracellular redox state. Biochim Biophys Acta. 1995;1269:153-161.
112. Niknahad H, Khan S, O'Brien PJ. Hepatocyte injury resulting from the inhibition of mitochondrial respiration at low oxygen concentrations involves reductive stress and oxygen activation. Chem Biol Interact. 1995;98:27-44.
113. Masubuchi Y, Suda C, Horie T. Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J Hepatol. 2005;42:110-116.
114. Ramsay RR, Rashed MS, Nelson SD. In vitro effects of acetaminophen metabolites and analogs on the respiration of mouse liver mitochondria. Arch Biochem Biophys. 1989;273:449-457.
115. Ludwig LM, Tanaka K, Eells JT, et al. Preconditioning by isoflurane is mediated by reactive oxygen species generated from mitochondrial electron transport chain complex III. Anesth Analg. 2004;99:1308-1315.
116. Riess ML, Kevin LG, McCormick J, Jiang MT, Rhodes SS, Stowe DF. Anesthetic preconditioning: the role of free radicals in sevoflurane-induced attenuation of mitochondrial electron transport in guinea pig isolated hearts. Anesth Analg. 2005;100:46-53.
117. Yoshikawa S, Muramoto K, Shinzawa-Itoh K, et al. Reaction mechanism of bovine heart cytochrome c oxidase. Biochim Biophys Acta. 2006;1757:395-400.
118. Kiyomiya K, Matsushita N, Matsuo S, Kurebe M. Cephaloridine-induced inhibition of cytochrome c oxidase activity in the mitochondria of cultured renal epithelial cells (LLC-PK(1)) as a possible mechanism of its nephrotoxicity. Toxicol Appl Pharmacol. 2000;167:151-156.
119. Kiyomiya K, Matsushita N, Kurebe M, Nakagawa H, Matsuo S. Mitochondrial cytochrome c oxidase as a target site for cephalosporin antibiotics in renal epithelial cells (LLC-PK(1)) and renal cortex. Life Sci. 2002;72:49-57.
120. Kohda Y, Gemba M. Cephaloridine induces translocation of protein kinase C delta into mitochondria and enhances mitochondrial generation of free radicals in the kidney cortex of rats causing renal dysfunction. J Pharmacol Sci. 2005;98:49-57.
121. Tune BM, Hsu CY. The renal mitochondrial toxicity of cephalosporins: specificity of the effect on anionic substrate uptake. J Pharmacol Exp Ther. 1990;252:65-69.
122. Benbrik E, Chariot P, Bonavaud S, et al. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci. 1997;149:19-25.
123. Lamperth L, Dalakas MC, Dagani F, Anderson J, Ferrari R. Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model. Lab Invest. 1991;65:742-751.
124. de la Asuncion JG, Del Olmo ML, Gomez-Cambronero LG, Sastre J, Pallardo FV, Vina J. AZT induces oxidative damage to cardiac mitochondria: protective effect of vitamins C and E. Life Sci. 2004;76:47-56.
125. Moreno SN. Pentamidine is an uncoupler of oxidative phosphorylation in rat liver mitochondria. Arch Biochem Biophys. 1996;326:15-20.
126. Garlid KD, Nakashima RA. Studies on the mechanism of uncoupling by amine local anesthetics: evidence for mitochondrial proton transport mediated by lipophilic ion pairs. J Biol Chem. 1983;258:7974-7980.
127. Somasundaram S, Sigthorsson G, Simpson RJ, et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther. 2000;14:639-650.
128. Masubuchi Y, Yamada S, Horie T. Diphenylamine as an important structure of nonsteroidal anti-inflammatory drugs to uncouple mitochondrial oxidative phosphorylation. Biochem Pharmacol. 1999;58:861-865.
129. Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl Pharmacol. 2003;192:307-322.
130. Inoue A, Muranaka S, Fujita H, Kanno T, Tamai H, Utsumi K. Molecular mechanism of diclofenac-induced apoptosis of promyelocytic leukemia: dependency on reactive oxygen species, Akt, Bid, cytochrome and caspase pathway. Free Radic Biol Med. 2004;37:1290-1299.
131. Tay VK, Wang AS, Leow KY, Ong MM, Wong KP, Boelsterli UA. Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro. Free Radic Biol Med. 2005;39:949-959.
132. Berson A, Cazanave S, Descatoire V, et al. The anti-inflammatory drug, nimesulide (4-nitro-2-phenoxymethane-sulfoanilide), uncouples mitochondria and induces mitochondrial permeability, transition in human hepatoma cells: protection by albumin. J Pharmacol Exp Ther. 2006;318:444-454.
133. Basivireddy J, Jacob M, Pulimood AB, Balasubramanian KA. Indomethacin-induced renal damage: role of oxygen free radicals. Biochem Pharmacol. 2004;67:587-599.
134. Cardoso CM, Custodio JB, Almeida LM, Moreno AJ. Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. Toxicol Appl Pharmacol. 2001;176:145-152.
135. Cardoso CM, Moreno AJ, Almeida LM, Custodio JB. Comparison of the changes in adenine nucleotides of rat liver mitochondria induced by tamoxifen and 4-hydroxytamoxifen. Toxicol in vitro. 2003;17:663-670.
136. Hynes J, Marroquin LD, Ogurtsov VI, et al. Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes. Toxicol Sci. 2006;92:186-200.
137. Sun X, Garlid KD. On the mechanism by which bupivacaine conducts protons across the membranes of mitochondria and liposomes. J Biol Chem. 1992;267:19147-19154.
138. Sztark F, Malgat M, Dabadie P, Mazat JP. Comparison of the effects of bupivacaine and ropivacaine on heart cell mitochondrial bioenergetics. Anesthesiology. 1998;88:1340-1349.
139. Irwin W, Fontaine E, Agnolucci L, et al. Bupivacaine myotoxicity is mediated by mitochondria. J Biol Chem. 2002;277:12221-12227.
140. Floridi A, Di Padova M, Barbieri R, Arcuri E. Effect of local anesthetic ropivacaine on isolated rat liver mitochondria. Biochem Pharmacol. 1999;58:1009-1016.
141. Curti C, Mingatto FE, Polizello AC, Galastri LO, Uyemura SA, Santos AC. Fluoxetine interacts with the lipid bilayer of the inner membrane in isolated rat brain mitochondria, inhibiting electron transport and F1FO-ATPase activity. Mol Cell Biochem. 1999;199:103-109.
142. Acco A, Comar JF, Bracht A. Metabolic effects of propofol in the isolated perfused rat liver. Basic Clin Pharmacol Toxicol. 2004;95:166-174.
143. Chen RM, Wu CH, Chang HC, et al. Propofol suppresses macrophage functions and modulates mitochondrial membrane potential and cellular adenosine triphosphate synthesis. Anesthesiology. 2003;98:1178-1185.
144. Borges N. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. Drug Saf. 2003;26:743-747.
145. Nissinen E, Kaheinen P, Penttila KE, Kaivola J, Linden IB. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Eur J Pharmacol. 1997;340:287-294.
146. Haasio K, Koponen A, Penttila KE, Nissinen E. Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur J Pharmacol. 2002;453:21-26.
147. Masubuchi Y, Yamada S, Horie T. Diphenylamine as an important structure of nonsteroidal anti-inflammatory drugs to uncouple mitochondrial oxidative phosphorylation. Biochem Pharmacol. 1999;58:861-865.
148. Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol. 2003;192:307-322.
149. Spaniol M, Bracher R, Ha HR, Follath F, Krahenbuhl S. Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J Hepatol. 2001;35:628-636.
150. Nakagawa Y, Tayama K. Mechanism of mitochondrial dysfunction and cytotoxicity induced by tropolones in isolated rat hepatocytes. Chem Biol Interact. 1998;116:45-60.
151. Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2007;23:15-25.
152. Hasinoff BB, Schnabl KL, Marusak RA, Patel D, Huebner E. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol. 2003;3:89-99.
153. Santos DL, Moreno AJ, Leino RL, Froberg MK, Wallace KB. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol. 2002;185:218-227.
154. Kang YJ, Sun X, Chen Y, Zhou Z. Inhibition of doxorubicin chronic toxicity in catalase-overexpressing transgenic mouse hearts. Chem Res Toxicol. 2002;15:1-6.
155. Yen HC, Oberley TD, Gairola CG, Szweda LI, St Clair DK. Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice. Arch Biochem Biophys. 1999;362:59-66.
156. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 2001;61:771-777.
157. Goormaghtigh E, Huart P, Praet M, Brasseur R, Ruysschaert JM. Structure of the adriamycin-cardiolipin complex: role in mitochondrial toxicity. Biophys Chem. 1990;35:247-257.
158. Lee CS, Park SY, Ko HH, Han ES. Effect of change in cellular GSH levels on mitochondrial damage and cell viability loss due to mitomycin C in small cell lung cancer cells. Biochem Pharmacol. 2004;68:1857-1867.
159. Park SY, Ko HH, Song JH, Han ES, Lee CS. Differential effect of nitrogen species on changes in mitochondrial membrane permeability due to mitomycin C in lung epithelial cells. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:312-321.
160. Hadler HI, Cook GL. A requirement of Pi for the transitory uncoupling of rat liver mitochondria by hydrazine, when beta-hydroxybutyrate is the substrate. J Environ Pathol Toxicol. 1978;1:419-432.
161. Hussain SM, Frazier JM. Cellular toxicity of hydrazine in primary rat hepatocytes. Toxicol Sci. 2002;69:424-432.
162. Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev. 1999;31:971-997.
163. Servais H, Van Der SP, Thirion G, Van der EG, Van Bambeke F, Tulkens PM, Mingeot-Leclercq MP. Gentamicin-induced apoptosis in LLC-PK1 cells: involvement of lysosomes and mitochondria. Toxicol Appl Pharmacol. 2005;206:321-333.
164. Lesniak W, Pecoraro VL, Schacht J. Ternary complexes of gentamicin with iron and lipid catalyze formation of reactive oxygen species. Chem Res Toxicol. 2005;18:357-364.
165. Liguori MJ, Anderson MG, Bukofzer S, et al. Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology. 2005;41:177-186.
166. Wakabayashi T. Megamitochondria formation: physiology and pathology. J CellMol Med. 2002;6:497-538.
167. Shishido S, Koga H, Harada M, Kumemura H, et al. Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. Hepatology. 2003;37:136-147.
168. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol . 1999;31:430-434.
169. Guastadisegni C, Balduzzi M, Mancuso MT, Di Consiglio E. Liver mitochondria alterations in chloroform-treated Sprague-Dawley rats. J Toxicol Environ Health A. 1999;57:415-429.
170. Hernandez-Munoz R, Sanchez-Sevilla L, Martinez-Gomez A, Dent MA. Changes in mitochondrial adenine nucleotides and in permeability transition in two models of rat liver regeneration. Hepatology. 2003;37:842-851.
171. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol. 2007;47:629-656.
172. Stockdale M, Selwyn MJ. Effects of ring substituents on the activity of phenols as inhibitors and uncouplers of mitochondrial respiration. Eur J Biochem. 1971;21:565-574.
173. Cronin MT, Manga N, Seward JR, Sinks GD, Schultz TW. Parametrization of electrophilicity for the prediction of the toxicity of aromatic compounds. Chem Res Toxicol. 2001;14:1498-1505.
174. Hansch C, McKarns SC, Smith CJ, Doolittle DJ. Comparative QSAR evidence for a free-radical mechanism of phenol-induced toxicity. Chem Biol Interact. 2000;127:61-72.
175. Moridani MY, Siraki A, O'Brien PJ. Quantitative structure toxicity relationships for phenols in isolated rat hepatocytes. Chem Biol Interact. 2003;145:213-223.
176. Argese E, Bettiol C, Giurin G, Miana P. Quantitative structure-activity relationships for the toxicity of chlorophenols to mammalian submitochondrial particles. Chemosphere. 1999;38:2281-2292.
177. Miyoshi H, Tsujishita H, Tokutake N, Fujita T. Quantitative analysis of uncoupling activity of substituted phenols with a physicochemical substituent and molecular parameters. Biochim Biophys Acta. 1990;1016:99-106.
178. Siraki AG, Chevaldina T, O'Brien PJ. Application of quantitative structure-toxicity relationships for acute NSAID cytotoxicity in rat hepatocytes. Chem Biol Interact. 2005;151:177-191.
179. Galati G, Tafazoli S, Sabzevari O, Chan TS, O'Brien PJ. Idiosyncratic NSAID drug induced oxidative stress. Chem Biol Interact. 2002;142:25-41.
180. Casanovas AM, Malmary Nebot MF, Courriere P, Oustrin J. Inhibition of cytochrome oxidase activity by local anaesthetics. Biochem Pharmacol.1983;32:2715-2719.
181. Stringer BK, Harmon HJ. Inhibition of cytochrome oxidase by dibucaine. Biochem Pharmacol. 1990;40:1077-1081.
182. Klein CD, Klingmuller M, Schellinski C, et al. Synthesis, pharmacological and biophysical characterization, and membrane-interaction QSAR analysis of cationic amphiphilic model compounds. J Med Chem. 1999;42:3874-3888.
183. Bandyopadhyay S, Klaunig JE, Somani P. Cytotoxic interactions of cardioactive cationic amphiphilic compounds in primary rat hepatocytes in culture. Hepatology. 1990;12:48-58.
184. Lullmann H, Lullmann-Rauch R, Wassermann O. Lipidosis induced by amphiphilic cationic drugs. Biochem Pharmacol. 1978;27:1103-1108.
185. Ploemen JP, Kelder J, Hafmans T, et al. Use of physicochemical calculation of pKa and C Log P to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. Exp Toxicol Pathol. 2004;55:347-355.
186. Tomizawa K, Sugano K, Yamada H, Horii I. Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. J Toxicol Sci. 2006;31:315-324.
187. Dykens JA, Will Y. Significance of mitochondrial toxicity testing in drug development. Drug Dev Today. 2007;12:777-785.